FindTrial
Sign In

Clinical translational research on the integration of diagnosis and treatment of Her2-positive breast cancer with dual-mode radionuclide/fluorescence drugs

Clinical translational research on the integration of diagnosis and treatment of Her2-positive breast cancer with dual-mode radionuclide/fluorescence drugs

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118518
Enrollment
Unknown
Registered
2026-02-06
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Her2-positive breast cancer.

Interventions

HER2-Positive Cohort:131I-ICG-Trastuzumab

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age >=18 years and <=70 years; 2. Physically able to tolerate the examination or procedure; 3. Pathologically confirmed breast cancer patients with high HER2 expression; 4. No recent targeted therapy/radiotherapy/chemotherapy; 5. Patient's hematological, hepatic, and renal function parameters meet the requirements.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Patients unable to cooperate to complete the examination, such as those with poor self-care ability, severe claustrophobia, or critically ill patients requiring life support; 3. Patients with other conditions unsuitable for this examination; 4. Patients with relevant allergies. 5. Patients planning pregnancy.

Design outcomes

Primary

MeasureTime frame
sensitivity;accuracy;specificity;Optimal imaging time/dose;—

Countries

China

Contacts

Public ContactZhi Lu

The First Affiliated Hospital of Dalian Medical University

luzhi@firsthosp-dmu.com+86 411 8439 4963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026